Literature DB >> 11391719

Recurrent thromboembolic disease following splenectomy for pyruvate kinase deficiency.

R Chou1, T G DeLoughery.   

Abstract

We report a case of recurrent thromboembolic disease and chronic pulmonary hypertension in an adult patient with pyruvate kinase deficiency who underwent splenectomy as a child. Thromboembolism has been reported as a complication following splenectomy for various hereditary chronic hemolytic anemias. To our knowledge, this association has not been described in patients specifically with pyruvate kinase deficiency. Our patient presented at age 37 with recurrent pulmonary emboli, 36 years after splenectomy for severe hemolytic anemia. Work-up for other hypercoagulable states was negative. The mechanism for hypercoagulability in this condition is unclear but may involve a quantitative or qualitative change in disrupted thrombogenic red blood cell membranes that would normally be removed by the spleen. Clinicians should have a high index of suspicion for thrombotic events in these patients, as early diagnosis and treatment can reduce morbidity and mortality, and chronic anticoagulation may help prevent the sequelae of repeated thromboembolic events. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11391719     DOI: 10.1002/ajh.1107

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  21 in total

1.  Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!

Authors:  Mark T Gladwin; Gregory J Kato
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

2.  Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.

Authors:  Mark T Gladwin; Gregory J Kato
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

3.  Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.

Authors:  Roberto F Machado; Mark T Gladwin
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

4.  Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease.

Authors:  Claudia R Morris; Gregory J Kato; Mirjana Poljakovic; Xunde Wang; William C Blackwelder; Vandana Sachdev; Stanley L Hazen; Elliott P Vichinsky; Sidney M Morris; Mark T Gladwin
Journal:  JAMA       Date:  2005-07-06       Impact factor: 56.272

5.  Splenectomy and chronic thromboembolic pulmonary hypertension.

Authors:  X Jaïs; V Ioos; C Jardim; O Sitbon; F Parent; A Hamid; E Fadel; P Dartevelle; G Simonneau; M Humbert
Journal:  Thorax       Date:  2005-08-05       Impact factor: 9.139

6.  Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline.

Authors:  Sanjay Mehta; Doug Helmersen; Steeve Provencher; Naushad Hirani; Fraser D Rubens; Marc De Perrot; Mark Blostein; Kim Boutet; George Chandy; Carole Dennie; John Granton; Paul Hernandez; Andrew M Hirsch; Karen Laframboise; Robert D Levy; Dale Lien; Simon Martel; Gerard Shoemaker; John Swiston; Justin Weinkauf
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

7.  A case of severe pyruvate kinase deficiency in a primigravida: successful outcome.

Authors:  Sahar Mohamed; Kenga Sivarajah; Seema Chakravarti
Journal:  Obstet Med       Date:  2013-05-03

Review 8.  Pleiotropic effects of intravascular haemolysis on vascular homeostasis.

Authors:  Gregory J Kato; James G Taylor
Journal:  Br J Haematol       Date:  2009-12-01       Impact factor: 6.998

Review 9.  Vascular complications after splenectomy for hematologic disorders.

Authors:  Shelley E Crary; George R Buchanan
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

10.  Pulmonary hypertension in patients with hematological disorders following splenectomy.

Authors:  V Meera; Farah Jijina; Kanjaksha Ghosh
Journal:  Indian J Hematol Blood Transfus       Date:  2010-08-04       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.